ǰÑÔ
¸ß֬Ѫ֢(hyperlipidemia)ÊÇÒ»ÖÖÈ«ÉíÐÔ¼²²¡£¬Í¨³£ÊÇָѪÖÐ×ܵ¨¹Ì´¼ºÍ£¨»ò£©¸ÊÓÍÈýõ¥¹ý¸ß¡£Ñ¡ÔñºÏÊʵ͝ÎïÄ£×ÓÊÇÑо¿¸ß֬Ѫ֢µÄÒªº¦¡£Ò»Ñùƽ³£¶øÑÔ£¬Ñ¡Óøß֬Ѫ֢ģ×ӵ͝ÎӦ¸ÃÔÚѪ½¬Ö¬ÂѰ××é³É¡¢¸ÎÔ൨¹Ì´¼¼°Ö¬ÂѰ״úлµÈ·½Ã棬ÓëÈËÀà´úÐ»ÌØÕ÷¼«ÎªÏà½ü¡£ÏêϸÌåÏÖΪ£ºµÚÒ»£¬×ܵ¨¹Ì´¼ºÏ³ÉÁ¿ÖÐÓɸÎÔàºÏ³ÉµÄÁ¿Ô½Ð¡Ô½ºÃ£»µÚ¶þ£¬ÔöÌíÒûʳÖе¨¹Ì´¼º¬Á¿²»»áÒýÆðµ¨ÖËáºÏ³ÉÔöÌí¡¢²»À©³äµ¨¹Ì´¼´úл³Ø¡¢²»ÒÖÖÆµÍÃܶÈÖ¬ÂѰ×ÊÜÌå»îÐÔ¡¢²»ÍêÈ«ÒÖÖÆ¸Îµ¨¹Ì´¼µÄºÏ³É£»µÚÈý£¬¸ßÖ¬Òûʳ¿ÉÒÔÓÕµ¼¸ß¸ÊÓÍÈýõ¥ÑªÖ¢¡£
ÓÉÓÚСÊóµÄ»ùÒòÐÞÊÎÊÖÒÕÒѾ³ÉÊ죬»ùÓÚ»ùÒòÐÞÊζ¯ÎïÄ£×ÓÔÚ¼²²¡Ñо¿ÖеÄÓÅÊÆ£¬¸ßµ¨¹Ì´¼ÑªÖ¢»ùÒòÐÞÊÎСÊóµÄÆÕ±éÓ¦Ó㬴ó´óÍÆ½øÁË´úлÐÔÐÄѪ¹Ü²¡µÄ¿ÆÑ§Ï£Íû¡£È»¶ø£¬Ð¡ÊóºÍÈËÀàÔÚÖ¬´úл·½ÃæÓÐÖØ´óµÄ²î±ð£¬ÀýÈçѪ½¬Ö¬ÂÑ°×Æ×²î±ð¡¢¶ÔʳÎï·´Ó¦ÐÔ²î±ð¡¢´úлø±í´ï²î±ð¡¢¸ÊÓÍÈýõ¥´úл²î±ð¶Ô½µÖ¬Ò©·´Ó¦²î±ðµÈ¡£Ëæ×ÅÑо¿µÄÉîÈëºÍÀ©Õ¹£¬¼±ÐèѰÕÒ¿ª·¢ÓëÈËÀàÖ¬´úл¸üΪ¿¿½üµÄ¶¯Îï¡£´Ó±¾Ç®¡¢×ÌÉúËÙÂÊ¡¢ÊµÑé²Ù×÷¡¢ÓëÈËÀàÏàËÆÐÔ¡¢»ùÒòÐÞÊÎÊÖÒÕ¡¢Â×ÀíѧµÈ·½Ãæ×ÛºÏÆÊÎö£¬½ð»ÆµØÊó¡¢¼ÒÍá¢Ð¡ÐÍÖíÊÇÊÊÊÊÓÃÓÚ¸ß֬Ѫ֢¼°Æä²¢·¢Ö¢Ñо¿µÄ¶¯Îï¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î¼ÒÍᢴóÊó¡¢Ð¡Êó
¡¾ÔìÄ£»úÖÆ¡¿£º
ÏÖÔÚΪֹ£¬»¹Ã»ÓÐ×÷Óý³ö´¿´â×Ô¾õÐԸ߸ÊÓÍÈýõ¥ÑªÖ¢(hypertriglyceridemia)¶¯ÎïÄ£×Ó£¬ÓÐЩ×Ô¾õÐÔÌÇÄò²¡Ä£×Ó°éÓи߸ÊÓÍÈýõ¥ÑªÖ¢¡£×Ô¾õÐԸߵ¨¹Ì´¼ÑªÖ¢(hypercholesterolemia)Ä£×ÓÔòÒѾ½¨Éè¶à¸öƷϵ£¬°üÀ¨¶àÖÖ¶¯ÎïÖÖÀà¡£ÕâÀàÄ£×ӵĽ¨É裬¶¼ÊÇͨ¹ý±íÐÍɸѡ£¬ºã¾Ã½ü½»ÐγÉÒÅ´«Åä¾°Ò»Öµġ¢±íÐÍÎȹÌÒÅ´«µÄƷϵ¡£
¡¾Ä£×ÓÌØµã¡¿£º
¼ÒÍãºWHHL¼ÒÍÃÊÇÒ»¸öLDLrȱÏݵÄÄ£×ÓÆäÁÙ´²ÌØÕ÷ºÍ²¡Àíת±äÓëÈ˼Ò×åÐԸߵ¨¹Ì´¼ÑªÖ¢(familial hypercholesterolernia)ºÜÊÇÏàËÆ¡£STHSÍÃApoBÒì³£Ôö¶àµ¼ÖÂLDLºÍVLDLÔöÌí£¬Óë¼Ò×å»ìÏýÐÔ¸ß֬Ѫ֢ºÍ¸ßApoBÖ¬ÂѰ×Ѫ֢ÏàËÆ¡£JW/HLR¼ÒÍÃÊÇÒ»ÖÖÔ·¢ÐÔ¸ß֬Ѫ֢Ʒϵ£¬×ÐÍÃÒ»³öÉú¾Í·ºÆð¸ß֬Ѫ֢¡£µ½35ÔÂÁäʱ£¬´ó¶¯Âö±¬·¢¶¯ÂöÖàÑùÓ²»¯£¬ÓëÈËÀà¢óÐ͸ß֬Ѫ֢ÏàËÆ¡£
´óÊó£ºEXHC ´óÊóÓɵ¨¹Ì´¼Ãô¸ÐµÄJCL´óÊóºÍprague Dawley´óÊóÅàÓý¶øÀ´£¬¸ßµ¨¹Ì´¼ÒûʳËÇιʱVLDLºÍLDLµ¨¹Ì´¼ÏÔÖøÉý¸ß£¬´ÆÐÔ±ÈÐÛÐÔÑÏÖØ¡£µ«¸ÊÓÍÈýõ¥ÏÕЩ²»Éý¸ß¡£SHC´óÊóÊÇÔÚÅàÓýEXHc´óÊóÀú³ÌÖз¢Ã÷µÄ£¬10ÖÜÒÔǰѪÇ嵨¹Ì´¼Ò»Á¬Éý¸ß£¬10ÖÜÖ®ºóLDLÉý¸ßÔ½·¢ÏÔ×Å£¬ÓëÈËÀàÓÉÉö²¡ÒýÆðµÄ¸ß֬Ѫ֢ÏàËÆ¡£ALRºÍNAR´óÊóÊÇ×Ô¾õÐÔ¸ß֬Ѫ֢Åãͬ¶¯ÂöÓ²»¯Ö¢´óÊ󣬿ÉÓÃÓÚ¸ß֬Ѫ֢ºÍÔçÆÚ¶¯ÂöÖàÑùÓ²»¯µÄÑо¿¡£³öÉú25Ìì×óÓÒµÄÈéÓ×´óÊó£¬ÓÉÓÚ¼××´ÏÙ¹¦Ð§»¹²»½¡È«£¬ÔÚ¸ßÖ¬·¾Ä¸ÈéÏ£¬ÆäѪÇå×ܵ¨¹Ì´¼Ô¼¸ßÓÚ³ÉÄê´óÊóµÄ2~3±¶£¬¿É×÷ΪÏÈÌìÐԸߵ¨¹Ì´¼ÑªÖ¢¶¯ÎïÄ£×Ó¡£
СÊó£ºNJSСÊóÊǽÓÄɸ߶Ƚü½»Ó붨ÏòÑ¡ÓýÊÖ¶ÎÓý³ÉµÄ×Ô¾õÐԸߵ¨¹Ì´¼ÑªÖ¢¶¯ÎѪÇ嵨¹Ì´¼Ë®Æ½Éý¸ß2~3±¶¡£ddYСÊóÊÇÒ»Öֲͺó¸ß¸ÊÓÍÈýõ¥ÑªÖ¢Ä£×Ó£¬Æä²ÍºóLPL»îÐÔ²»ÏñC57BL/6ƷϵСÊóÉý¸ß£¬¸ÊÓÍÈýõ¥Ë®Æ½ÏÔÖøÉý¸ß5±¶£¬ÇÒɨ³ýºÜÂý¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
×Ô¾õÐÔ¸ß֬Ѫ֢¶¯ÎïÄ£×ÓÖ¢×´Îȹ̣¬¿ÉÒÅ´«£¬ÓëÈËÀà¸ß֬Ѫ֢µÄÐγɻúÖÆÓÐ×Ųî±ðˮƽµÄÏàËÆ¡£¿ÉÊÇ£¬ÓÉÓÚȪԴÄÑÌâ¡¢³ÉÄÚÇé¶Ô½Ï¸ß¡¢¿¹²¡ÄÜÁ¦²î¡¢²»Ò×ËÇÑøµÈÔµ¹ÊÔÓÉ£¬ÏÞÖÆÁËÆäÆÕ±éÓ¦Óá£
²Î¿¼ÎÄÏ×£º
1.Áõ¶÷᪣¬·¶½ÁØ£®×ª»ùÒòÍÃÔÚ¶¯ÂöÖàÑùÓ²»¯Ñо¿ÖеÄÓ¦Óü°Ï£Íû£®Öйú¶¯ÂöÓ²»¯ÔÓÖ¾£¬2003,11(4): 371-375
2.Al-Mashhadi RH,Sørensen CB,Kragh PM,et al.Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gainof-function mutant. Sci Transl Med,2013,5 (166): 166ral
3.Ding Y, Wang Y, Zhu H, et al. Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CID. Transgenic Res, 2011,20(4):867-875
4.Gao S, He L,Ding Y,el al. Mechanisms underlying different responses of plasma triglyceride to high-fat diels in hamsters and mice: roles of hepatic MTP and triglyceridesecretion. Biochem Biophys Res Commun,2010,398(4): 619-626
5.Getz GS,Reardon CA. Animal models of atherosclerosis.Arterioscler Thromb Vasc Biol, 2012, 32 (5):1104-1115
6.Stylianou IM, Bauer RC, Reilly MP, el al. Genetic basis of atherosclerosis:insights from mice and humans. Circ Res, 2012, 110(2):337-355
7.Wei J,Ouyang H, Wang Y,el al. Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII. FEBS J,2012,279 (1):91-99
8.Yin W, Carballo-Jane E, McLaren DG, et al. Plasma lipid profiling across species for the identification of optimal animal models of human dysl.ipidemia. J Lipid Res,2012, 53 (1):51-65
9.Zhang X, Qi R, Xian X, el al. Spontaneous atherosclerosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circ Res,2008,102 (2):250-256